The Joint Pharmaceutical Procurement Office of the State Organization announced on October 26 that letrozole tablets produced by Eugia Pharma Specialities Limited and gadolipic acid glucamine injections produced by JSC Farmak will be disqualified from collecting and winning the bid. The reason is that the reporting companies of the two companies mentioned above recently stated that they are unable to continue supplying products, and that they are still unable to meet the needs of medical institutions after interviews and supervision. Currently, Eugia Pharma Specialties Limited and its reporting companies Hangzhou Ketu Supply Chain Co., Ltd., JSC Farmak, and Shanghai Liyi Pharmaceutical Technology Co., Ltd. have all been included in the illegal list and disqualified from participating in national drug collection within 4 and 2 years.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.